Cerebral Sinus Vein Thrombosis and Gender: A Not Entirely Casual Relationship

Abstract

Cerebral sinus venous thrombosis (CSVT) is a relatively rare acute disorder of cerebral circulation, but it can potentially be associated with serious sequelae and a poor prognosis. The neurological manifestations associated with it are often not adequately taken into consideration given the extreme variability and nuances of its clinical presentation and given the need for radiological methods suitable for this type of diagnosis. CSVT is usually more common in women, but so far there are little data available in the literature on sex-specific characteristics regarding this pathology. CSVT is the result of multiple conditions and is therefore to be considered a multifactorial disease where at least one risk factor is present in over 80% of cases. From the literature, we learn that congenital or acquired prothrombotic states are to be considered extremely associated with the occurrence of an acute episode of CSVT and its recurrences. It is, therefore, necessary to fully know the origins and natural history of CSVT, in order to implement the diagnostic and therapeutic pathways of these neurological manifestations. In this report, we summarize the main causes of CSVT considering the possible influence of gender, bearing in mind that most of the causes listed above are pathological conditions closely linked to the female sex.

Investigating the Predictive Value of Thyroid Hormone Levels for Stroke Prognosis

“…These results contradict the findings of the included study in this review. The preceding highlights the need for additional research into the association between gender and thyroid hormones in stroke patients [ 68 , 69 ]. After a multivariate analysis, whose main goal was to identify independent risk variables for poor outcomes at 3 months, it was discovered that lower fT3 levels, age, NIHSS score, and no recanalization therapy were linked with worse functional outcomes.…”

Hemorrhagic Coagulation Disorders and Ischemic Stroke: How to Reconcile Both?

“…In the last decade, many steps forward have been made in the search for new anticoagulant drugs capable of acting on the pro-coagulative activity of some pathological conditions such as atrial fibrillation or congenital anomalies of the blood coagulation system (factor V deficiency Leiden, protein C, and protein S deficiency, hyperhomocysteinemia) [1,2]. New drugs have therefore been introduced, including direct anticoagulants, which are now key therapies in numerous pathological conditions and are added to antifibrinolytics, platelet inhibitors, and vitamin-K-dependent anticoagulants [1][2][3][4]. Their therapeutic benefits are indisputable; however, all evidence for these treatments must be balanced against the risk of bleeding complications, which are relatively frequent for some of these drugs.…”